Robin Myte

Featured in: Favicon

nature.com Favicon

jamanetwork.com Favicon

aacrjournals.org Favicon

gut.bmj.com Favicon

cebp.aacrjournals.org

Articles

Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial

Aug 14, 2024 | jamanetwork.com | Dalane W. Kitzman |Robert J. Mentz |Gregory Lewis |Robin Myte

Key PointsQuestion What are the effects of verinurad, a novel urate transporter–1 inhibitor, on exercise capacity and symptoms in patients with heart failure with preserved ejection fraction (HFpEF) and elevated serum uric acid (SUA) level?

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →